Huadong Medicine has made an announcement revealing that the clinical trial application for its Class 1 therapeutic biological agent, HDM2024 Injection (a bispecific antibody drug conjugate specifically targeting EGFR and HER3), which was submitted by its wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has successfully obtained approval. This particular drug is intended for the treatment of advanced solid tumors. Notably, HDM2024 has already been greenlit for Phase I clinical trials in the United States. Preclinical studies have underscored its promising anti-tumor activity, druggability, and safety profile. However, the company has clarified that this approval is not expected to exert a substantial influence on its recent financial performance, and it also acknowledges the inherent uncertainties associated with subsequent research and development endeavors.